---
title: "Mapping the proteo-genomic convergence of human diseases"
description: |
  * **Objective**: To construct a **proteo-genomic map** by systematically linking genetic risk for hundreds of human diseases and traits to variations in the levels of ~3,000 plasma proteins using data from >54,000 individuals.
  * **Key Result**: Identified **2,228 instances of genetic colocalization** across 1,440 proteins and 498 diseases/traits, indicating that a substantial portion of genetic disease risk is mediated by altered protein levels.
  * **Causal Inference**: Through Mendelian Randomization (MR), the study robustly predicted **44 proteins** to be **causally linked** to 37 diseases/traits (e.g., CRP and CAD), thereby providing high-priority candidates for drug targets.
date: last-modified
categories: [colocalization, disease mechanisms, genomics, mendelian randomization, pQTL, proteomics]
---

**PubMed:** [34648354](https://pubmed.ncbi.nlm.nih.gov/34648354/)
**DOI:** [10.1126/science.abj1541](https://doi.org/10.1126/science.abj1541)
**Overview generated by:** Gemini 2.5 Flash, 28/11/2025

## Key Findings: Linking Genetic Risk to Disease via Plasma Proteins

This study provides a comprehensive **"proteo-genomic map"** that links genetic risk for hundreds of human diseases and traits to changes in the levels of thousands of circulating plasma proteins. The core innovation is the systematic use of **genetic colocalization** to identify instances where the same genetic variant influences both a plasma protein level (as a pQTL) and a clinical disease/trait (as a GWAS hit).

The map provides two major insights:

1.  **Proteins Mediate Genetic Risk:** The study identified **2,228 instances of genetic colocalization** across 1,440 proteins and 498 diseases/traits. This finding suggests that a significant fraction of genetic disease risk acts by altering the level of a specific circulating protein.
2.  **Causal Inference and Drug Targets:** By integrating these colocalization events with **Mendelian Randomization (MR)**, the map pinpoints proteins that are likely to be **causally related** to a disease, making them high-priority candidates for therapeutic drug targeting.

### Colocalization and Mendelian Randomization
* **Colocalization:** The analysis used a Bayesian method to confirm that the genetic signal for a plasma protein (pQTL) and the genetic signal for a disease (GWAS) at a given locus are driven by the same causal variant. This identified **864 proteins** with a shared genetic signal with at least one clinical trait.
* **Causal Relationships:** Integrating this information with MR, the study identified **44 proteins** that were robustly predicted to be **causally linked** to 37 diseases/traits, often validating established biological pathways. For example, **C-reactive protein (CRP)** was found to be causally associated with increased risk for coronary artery disease and other inflammatory conditions.

## Methods and Design

### Data Sources
* **Proteomics:** Measured levels of **~3,000 plasma proteins** in over 54,000 individuals from the UK Biobank Pharma Proteomics Project (UKB-PPP) and other cohorts.
* **Genetics (pQTLs):** Genome-wide association study (GWAS) summary statistics for protein quantitative trait loci (pQTLs).
* **Disease/Trait Genetics (GWAS):** GWAS summary statistics for **498 diseases and complex traits**.

### Analytical Framework
1.  **GWAS for Proteins and Traits:** Conducted GWAS for all proteins and aggregated existing GWAS results for traits.
2.  **Genetic Colocalization:** Performed systematic colocalization analysis between all protein pQTLs and all trait GWAS loci to find shared genetic drivers.
3.  **Causal Inference (MR):** Applied Mendelian Randomization to the colocalized pairs to determine the likely **causal direction** (i.e., whether the protein level causes the disease or vice versa).
4.  **Knowledge Graph:** Constructed a **"proteo-genomic knowledge graph"** to visualize and connect the colocalized and causal protein-disease relationships. 

## Implications for Biology and Drug Discovery

### Convergence of Diseases
The proteo-genomic map revealed **convergence points** where the genetic signals for multiple diseases colocalized with the same protein. This means that genetic variation affecting a single protein can predispose an individual to several different, often seemingly unrelated, conditions (e.g., genetic variation at the **SULT2A1** locus linked to increased **SULT2A1 protein activity** and a higher risk of **gallstones**).

### Prioritization of Drug Targets
The study's causal protein-disease links provide a strong basis for prioritizing drug development. If a protein is causally linked to a disease, modulating that protein's level with a drug is likely to be therapeutically effective. The study validated known drug targets and also highlighted **new potential targets** based on the strength of the genetic evidence.

## Conclusions

The proteo-genomic map serves as a fundamental resource for understanding the molecular mechanisms underlying genetic disease risk. By demonstrating that genetic variation for many diseases converges on a shared set of plasma proteins, the study validates plasma proteomics as a key layer for translational medicine, facilitating drug target discovery and providing a causal foundation for biomarker development.